Publications

Skip to content

Publications

Explore Flatiron-authored research

Analysis of real-world progression and insufficient response variables and related endpoints among patients with non-Hodgkin lymphoma

Advances in Therapy

Richey M, Fullerton C, Zhang Q, et al

March 2025

publication-summary-analysis-of-real-world-progression-with-insufficient-response-variables-and-related-endpoints-among-patients-with-non-hodgkin-lymphoma

1,000 publications—and counting

To date, over 1,000 publications—authored by either Flatiron or our partners—have used Flatiron’s real-world data

Explore a list of all publications

See the impact of our data

Database Characterization Guide

An overview of Flatiron Health EHR-derived US data for journal reviewers and readers to better understand the data used in publications

Review our guide

Explore our summaries of Flatiron-authored research

Disease area

Acute myeloid leukemia

Breast cancer

Chronic lymphocytic leukemia

Colorectal cancer

Diffuse large B-Cell lymphoma

Gastric/Esophageal cancer

Head and neck cancer

Hepatocellular carcinoma

Melanoma

Metastatic breast cancer

Multiple myeloma

Non-small cell lung cancer

Ovarian cancer

Pancreatic cancer

Prostate cancer

Renal cell carcinoma

Small cell lung cancer

Tumor agnostic

Urothelial cell carcinoma

Topics

Comparative effectiveness

Drug discovery

HTA and market access

Health equity

Label expansion

Machine learning

Methodology

Prospective study

Quality improvement

Quality reporting

Regulatory

Resistance ID

Treatment patterns

Unmet need

Showing 9 of 0 results

Clinical Genitourinary Cancer
June 2025
Impact of renal function eligibility criteria in clinical trials and real world survival outcomes among patients with metastatic renal cell carcinoma
Wang X, Hasler J, Miron B, et al.
ASCO Annual Conference
May 2025
A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC)
Saverno K, Halloran S, Guinter M, et al.
ASCO Annual Meeting
May 2025
Molecular residual disease (MRD) in solid tumors
Ghanim M, Nemunaitis J, Marti T, et al.
ASCO Annual Conference
May 2025
Impact of social determinants of health on mortality in diffuse large B-cell lymphoma (DLBCL) using real-world data
Canavan M, Wang M, Mbah O, et al.
ASCO Annual Meeting
May 2025
Concordance of response-based clinical trial and machine learning–generated real-world end points
Zhang Q, Krismer K, Lu Y, et al.
ASCO Annual Meeting
May 2025
Real-world surgical and treatment patterns after neoadjuvant checkpoint inhibition in US patients with stage II/III non-small cell lung cancer
Lee J, Simmons D, Mulrooney T, et al.
ASCO Annual Meeting
May 2025
Real-world patient characteristics, treatment patterns, and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC): insights by PTEN status
Rathkopf D, Zhao D, Kovacevic L, et al.
ASCO Annual Meeting
May 2025
A retrospective cohort study of real-world clinical outcomes in patients with CLL/SLL previously treated with covalent BTK inhibitor (cBTKi) and BCL2 inhibitor (BCL2i) regimens
Prescott J, Parrinello C, Sawas A, et al.
ASCO Annual Meeting
May 2025
Accrual of racially and ethnically underrepresented populations with multiple myeloma associated with centralized patient screening in a multicenter study
Afghahi A, Sanchez D, Lu Y, et al.

Reimagining the infrastructure of cancer care

Resources
Publications
Company
Media
Careers
Contact Us

Clinical Research
Real-World Evidence
Point of Care

Legal, Privacy, and Compliance
Data Confidentiality Commitments
Cookie Settings
© FLATIRON HEALTH® 2025